Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Down 27.5% in February

Check-Cap Ltd. (NASDAQ:CHEK) was the recipient of a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 116,000 shares, a decrease of 27.5% from the January 31st total of 159,900 shares. Approximately 2.7% of the company’s shares are short sold. Based on an average daily volume of 1,350,000 shares, the short-interest ratio is presently 0.1 days.

Check-Cap Stock Down 2.7 %

Shares of NASDAQ CHEK traded down $0.02 during midday trading on Tuesday, hitting $0.79. The stock had a trading volume of 42,968 shares, compared to its average volume of 1,012,975. Check-Cap has a 1-year low of $0.56 and a 1-year high of $3.45. The company has a market capitalization of $4.62 million, a price-to-earnings ratio of -0.26 and a beta of 0.16. The company has a fifty day moving average price of $1.11 and a 200 day moving average price of $1.23.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on shares of Check-Cap in a report on Saturday. They issued a “sell” rating on the stock.

Check-Cap Company Profile

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.